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Abbreviations 
DALI® - polyacrylate whole blood adsorption; FAME – fatty acid methyl ester; FH – familial 
hypercholesterolemia; GC-FID – gas chromatography with flame ionization detection; hsCRP – high 
sensitivity C-reactive protein; MP – microparticle; NTA – nanoparticle tracking analysis; PDSA – 
plasma dextran sulphate adsorption; PS – phosphatidylserine; TC – total serum cholesterol ; TF – 
tissue factor; TRPS – tuneable resistive pulse sensing; WBDSA – whole blood dextran sulphate 
adsorption 
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Abstract 
Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. 
However, reduction is transient indicating the long-term cardiovascular benefits of apheresis may not 
solely be due to LDL removal. Microparticles (MPs) are submicron vesicles released from the plasma 
membrane of cells. MPs, particularly platelet-derived MPs, are increasingly being linked to the 
pathogenesis of many diseases. We aimed to characterize the effect of apheresis on MP size, 
concentration, cellular origin and fatty acid concentration in individuals with familial 
hypercholesterolemia (FH). Plasma and MP samples were collected from twelve individuals with FH 
undergoing routine apheresis. Tunable resistive pulse sensing (TRPS - np200) and nanoparticle 
tracking analysis (NTA) measured a fall in MP concentration (33% and 15% respectively, p<0.05) 
pre to post-apheresis. Flow cytometry showed MPs were predominantly Annexin V positive and of 
platelet (CD41) origin both pre- (88.9%) and post- (88.4%) apheresis. Fatty acid composition of MPs 
differed to that of plasma, though apheresis affected a similar profile of fatty acids in both 
compartments as measured by gas chromatography-flame ionization detection (GC-FID). MP 
concentration was also shown to positively correlate with thrombin generation potential. In 
conclusion, we show apheresis non-selectively removes Annexin V positive platelet-derived MPs in 
individuals with FH. These MPs are potent inducers of coagulation and are elevated in cardiovascular 
disease; this reduction in pathological MPs could relate to the long-term benefits of apheresis. 
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Introduction 
Familial hypercholesterolaemia (FH) is a common genetic disorder that causes elevated levels of 
atherogenic lipoproteins in the plasma, particularly low-density lipoprotein cholesterol (LDL). Over 
85% of FH cases are caused by mutations in the LDL receptor rendering these receptors unable to 
bind or internalise LDL and leading to accumulation in the plasma
1
. The disease follows an autosomal 
dominant pattern of inheritance and can result in heterozygote, or more serious homozygote forms
2
. In 
severe forms of FH, diet alteration and lipid lowering medications are often insufficient to lower LDL 
levels enough to abate atherosclerotic plaque formation
3
. These patients therefore require frequent (bi-
weekly) lipoprotein-apheresis (hereafter referred to as “apheresis”)  treatments in combination with 
dietary and pharmacological intervention to control LDL levels
4
.  
Apheresis is a safe, well established procedure for the extracorporeal removal of LDL. Blood is 
removed from one arm and passed through a column to remove atherogenic lipoproteins before being 
returned to the body via the other arm. Different apheresis techniques may be utilised, but all reduce 
LDL by approximately 70% immediately following treatment 
5–9
. However, post-treatment LDL 
levels are not maintained with levels rising to 50% of pre-treatment values within 2-4 days
10
. Despite 
this transiency, apheresis is associated with superior long-term cardiovascular benefits compared with 
alternative therapies
11–15
. 
Microparticles (MPs) are heterogeneous submicron vesicles released from many different cell types. 
Several terms exist to describe these vesicles, though here we use “MPs” as an umbrella term to 
encompass vesicles ranging from 30 nm – 1 µm in diameter. This range includes both exosomes and 
microvesicles. Exosomes are classically 30 – 100 nm in size and are produced from intracellular 
processing of endocytosed material which is then incorporated into exosomes and released from the 
cell by exocytosis. Microvesicles are vesicles ranging from 100 nm - 1µm released directly from the 
plasma membrane of cells in response to cellular activation or apoptosis. The phospholipid 
asymmetry of the cells’ plasma membrane is disrupted and consequently phosphatidylserine (PS) is 
externalised to the outer membrane. This is commonly used to identify microvesicle populations via 
Annexin V binding. MPs are released both in vivo and in vitro into the external environment of many 
cell types, allowing subsequent isolation from biological fluids or conditioned culture media
16
.  
Increased numbers of MPs, particularly those derived from platelets, have been reported in many 
cardiovascular diseases (CVD)
17,18
 though their function in both health and disease remains poorly 
understood. The surface of platelet MPs is reportedly up to 100-fold more procoagulant than that of 
activated platelets due to an increased density of PS, P-selectin and factor X
19
. Furthermore, MPs are 
known to carry specific mRNAs, microRNAs (miRs), proteins and lipid signalling molecules.  These 
bioactive entities are thought to be delivered to target cells though the mechanism by which this 
interaction occurs is still unknown
20
. To date, little is known about the lipid concentration and profile 
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of MPs, though platelet MPs have been shown to transfer proinflammatory lipids to platelets leading 
to activation
20
. 
 Heterozygous FH patients have previously been shown to have increased circulating levels of 
endothelial- and leukocyte-derived MPs compared to non-FH hypercholesterolaemia patients
21
. 
However, quantification of MPs in this study was achieved using flow cytometry which is not 
considered optimal due to the techniques’ lack of sensitivity for particles <200 nm. To our knowledge, 
no data exists detailing the effects of apheresis on MPs in individuals with FH, though other 
extracorporeal methods have been previously shown to remove MPs
22,23
. 
Here we aimed to characterise size, concentration, cellular origin, fatty acids and thrombin generation 
of MPs in FH patients undergoing apheresis, hypothesizing that this treatment would reduce 
circulating MPs as well as LDL. 
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Methods 
Patients  
Twelve patients with clinically significant dyslipidaemia undergoing fortnightly apheresis consented 
to take part in the study. For clinical reasons patients underwent treatment using three different 
techniques: polyacrylate whole blood adsorption (DALI®; n=8), whole blood- (WB; n=1), or plasma- 
(P; n=3) dextran sulphate adsorption (DSA) as described previously
24
. Patients attended the Lipid Unit 
at University Hospital Llandough, Cardiff for apheresis treatment as part of their normal clinical care. 
Patients fasted for at least 4 hours prior to attendance and took their prescribed medication for at least 
1 hour prior to the study, excluding vasoactive medications from which patients were asked to refrain. 
Routine anthropometric measurements were carried out prior to apheresis treatment. After 15 minutes 
of rest, vascular access was gained using 16 gauge 25 mm fistula needles into 2 anatomically distinct 
upper limb veins or by arterio-venous fistula. Blood samples were then drawn sequentially prior to 
and immediately after completion of apheresis, approximately 3 hours later. Seven healthy volunteers 
(free of CVD and medication) were also recruited to the study to compare MP concentration, size 
distribution, cellular origin and fatty acid profile with FH individuals. Ethical approval for obtaining 
blood samples was provided by the South East Wales Research Ethics Committee. 
 
Biochemical Measurements 
Blood samples were collected as described above into ethylenediaminetetraacetic acid (EDTA) and 
citrate vacutainers.  An Aerostat automated analyser (Abbott Diagnostics, Berkshire, UK) was used to 
measure serum total cholesterol (TC), HDL and triglycerides; LDL was then estimated using the 
Friedwald equation. Glucose levels were determined by using the Aerostat chemistry system (Abbott 
Diagnostics, Berkshire, UK) and high sensitivity CRP (hsCRP) was measured using nephelometry 
(BN™ II system, Dade Behring, UK). Blood pressure (BP) measurements were taken with patients 
seated using the Vicorder system (Skidmore Medical, UK) as part of a separate study. 
 
MP isolation 
Blood, collected as above, was immediately centrifuged (1509 x g, 10 mins, 4°C) to obtain platelet-
poor plasma (PPP). EDTA plasma was snap frozen in liquid nitrogen. Citrate plasma was 
ultracentrifuged (100,000 x g, 1 hour, 4°C) and the MP pellet was resuspended in either PBS and snap 
frozen in liquid nitrogen (for GC analysis), or in PBS containing 0.05% (v/v) Tween 20 (for MP size 
and concentration). The latter was then passed through a 1 µm filter (Supelco, Sigma Aldrich, UK) 
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and slow frozen overnight at -80°C in a Mr Frosty (Nalgene, Thermo Scientific, UK). Plasma and 
MPs were maintained at -80°C until analysis. 
 
MP size and concentration  
Two techniques were used to measure MP size and concentration: tunable resistive pulse sensing 
(TRPS) and nanoparticle tracking analysis (NTA). TRPS was carried out using the qNano (Izon 
Science, New Zealand) which uses an electrophoresis-based method to determine the size and 
concentration of MPs on a particle-by-particle basis. Particles pass through a tunable nanopore which 
detects particles within a specific size range. Therefore, in order to analyse MP size and concentration 
across a full spectrum, nanopores “100” and “200” (np100 and np200) were used. NTA was 
undertaken using the NanoSight LM10 (NanoSight Ltd, UK) with settings as previously described 
25
 
using the NTA software (version 2.3). NTA uses the light scattering by MPs and tracks their 
Brownian motion in suspension over time to relate this to MP size and concentration. Sixty second 
videos were recorded in replicates of five per sample with camera sensitivity and detection threshold 
set to (14-16) and (5-6) respectively.  
 
Microparticle origin 
Flow cytometry was used to determine MP origin using a custom-built BD FACSAria II (BD 
Biosciences, CA). Forward and side scatter area (FSC-A and SSC-A respectively) were set to log 
scale and MPs were gated based on their FSC-A/SSC-A profile and in relation to platelets in fresh 
plasma. MP pellets were resuspended in 1x 0.22 µm-filtered Annexin V binding buffer (BD 
Biosciences, CA) and 100 µL of this was used for staining. MPs were stained in the dark (15 mins, 
RT) with Annexin V-FITC (1.57 µg/mL), CD41-PE-Cy5 (0.12 µg/mL), CD11b-PE-Cy7 (7.9 µg/mL), 
CD144-APC (4.1 µg/mL) and CD235a-PB (7.7 µg/mL) as markers of MPs, platelets, monocytes, 
endothelial cells and erythrocytes respectively (all antibodies from Biolegend, CA). Data were 
exported from the FACSDiva™ software (version 6) and subsequently analysed in FlowJo software 
(version 9.6.4; Tree Star Inc., OR). 
 
MP fatty acid profile 
Fatty acid profiles were analysed using gas chromatography with flame ionisation detection (GC-FID) 
as described previously
26
. Briefly, lipids were extracted from 200 µL of plasma or isolated MP 
samples (250 µL) with chloroform : methanol (1:2, v/v) by the method of Garbus et al
27
. Fatty acid 
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methyl esters (FAME) were prepared by incubation for 2 hours with 2.5% H2SO4 in dry methanol: 
toluene (2:1, v/v) at 70°C. A known amount of C19:0 (nonadecylic acid, Nu-Chek Prep. Inc., Elysian, 
MN, USA) was added as an internal standard, so that subsequent quantification of peaks (and, 
consequently, lipids) could be performed. FAME were analysed by gas chromatography (GC) using a 
Clarus 500 gas chromatograph (Perkin-Elmer 8500, Norwalk, CT), fitted with a 30 m × 0.25 mm i.d., 
0.25 µm film thickness capillary column (Elite 225, Perkin-Elmer). The column temperature was held 
at 170°C for 3 minutes, then temperature-programmed to 220°C at 4°C/min. Nitrogen was the carrier 
gas at a flow rate 2 mL/min. FAME were identified routinely by comparing retention times of peaks 
with those of standard (Supelco 37 Component FAME Mix, Sigma Aldrich, UK, Nu-Chek Prep. Inc., 
USA). Perkin-Elmer Total Chrom Navigator software was used for data acquisition. 
 
MP thrombin generation 
To provide a working reservoir of plasma in which to test thrombin generation of MP, blood was 
drawn gently from healthy volunteers into a syringe containing 6 mM trisodium citrate (Sigma 
Aldrich, UK) and 20 µg/mL corn trypsin inhibitor (Cambridge BioScience, UK) and centrifuged 
(1024 x g, 10 minutes, 4°C) to yield “vehicle” PPP. Samples were then stored at -80°C until analysis. 
To asses MP thrombin generation, calibrated automated thrombography (CAT) was used as described 
previously
28
 with minor modifications. Samples were measured in duplicate using 96-well plates 
(round-bottomed, Immulon 2HB, Thermo Scientific, UK). Eighty µL of vehicle PPP (containing 
endogenous clotting factors) was added to each well with 20 µL of diluted (HEPES/NaCl buffer, pH 
7.4) tissue factor solution to yield a final concentration of 1 pM (Innovin, Sysmex UK Ltd, UK). FH 
MP samples were assayed for thrombin generation both with and without exogenous tissue factor 
(TF) addition. Therefore, MPs (20 µL) were added to sample wells with the addition of either saline 
(20 µL, 0.9% NaCl) or TF (20 µL, 1pM final). Each sample was calibrated to a well containing 80 µL 
of PPP and 40 µL of thrombin calibrator (600 nM, Synapse BV, Netherlands). The plate was then 
warmed to 37°C for 5 minutes before addition of fluorogenic substrate (20 µL, Z-Gly-Gly-Arg-AMC, 
Bachem, UK ). The fluorescent signal was then measured using a Fluoroskan Ascent plate reader 
(ThermoLabsystems, Finland) equipped with a 390/460 nm filter set (excitation/emission) at 15 s 
intervals until the thrombin generation reaction was complete. Data were analysed using 
Thrombinoscope™ software (Synapse BV, Netherlands) and correlated with MP concentration data. 
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Statistical Analysis 
Data are presented as means ± SEM. A paired t-test (two-tailed) or a Wilcoxon matched pairs test was 
used for parametric and non-parametric data respectively. Analyses were conducted using GraphPad 
Prism (version 6; GraphPad Software Inc., CA) and a p value <0.05 was considered statistically 
significant. 
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Results 
Anthropometric and biochemical data 
Of the twelve participants in the study, 9 were male and 3 female with a mean age of 57.9 ± 10.3 
years and a mean BMI of 30.0 ± 4.0 kg/m². Biochemical measurements are summarised in Table 1. 
Apheresis reduced TC, triglycerides, HDL, LDL hsCRP and systolic BP. No changes were observed 
in glucose levels, diastolic BP or heart rate.  
 
MP size and concentration pre- versus post-apheresis 
Two techniques, TRPS (using np100 and np200) and NTA were used to analyze MP size and 
concentration, therefore the detectability was compared for each technique pre- and post-apheresis 
(Supplementary Figure: SIA and B). The size distribution of MPs was similar for TRPS (np100 and 
np200) and NTA though the measured concentration varied greatly between the two techniques. 
Mode size of MPs did not change following apheresis by any technique (81.1 ± 19.6 to 78.4 ± 16.7, 
p=0.3 for TRPS (np100), 170.3 ± 40.6 to 163.6 ± 29.2, p=0.18 for TRPS (np200) and 93.3 ± 21 to 
88.2 ± 14.7 nm, p=0.32: for NTA). TRPS (np100) measured no difference in concentration pre- to 
post-apheresis (4.6 x 10
11
 ± 1.3 x 10
11
 to 3.1 x 10
11
 ± 1.0 x 10
11
: p=0.18; Figure 1A). However, TRPS 
(np200) and NTA both measured a decrease in MPs pre- vs post-apheresis (4.7 x 10
10 
± 8.8 x 10
9 
to 
3.1 x 10
10 
± 5.6 x 10
9
,
 
and 1.9 x 10
12 
± 2.4 x 10
11 
to 1.5 x 10
12
 ± 2.4 x 10
11
 particles/mL: p=0.013 and 
0.025; Figure 1C and E for TRPS (np200) and NTA respectively). Total cholesterol was measured in 
the MP fraction and was below the detectability of the assay (<0.01 mmol/L). Size/concentration 
distributions of MPs are shown pre- to post-apheresis for each technique. TRPS (np100) and NTA 
show no preferential reduction according to MP size (Figure 1B and F respectively) whereas TRPS 
(np200) shows a reduction in MPs between 200-249 nm (Figure 1D, p=0.01). The type of apheresis 
received by patients was not shown to affect MP concentration (Supplemental Table SI); however the 
study was not powered to measure this as an endpoint.  Comparison of MPs in FH with healthy 
volunteers showed a trend (non-significant) towards an increase in total concentration however, the 
size distribution showed individuals with FH had increased concentrations of MPs between 50-100 
nm (p<0.05, Supplemental Figure SIIA/B respectively). 
 
Effect of apheresis on MP origin 
MPs falling within the MP gate (Figure 2A) showed no change in apportion of Annexin V positivity 
following apheresis (Figure 2B). Of these Annexin V positive MPs, there were also no changes in the 
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proportions derived from platelets (CD41), endothelial cells (CD144), monocytes (CD11b) or 
erythrocytes (CD235a), (Figure 2C). MPs positive for both Annexin V and CD41 accounted for the 
majority (~ 90%) of MPs measured. The same was also true for MPs in healthy volunteers, though 
there was a minor increase in the proportion of endothelial-derived MPs in individuals with FH 
compared to healthy volunteers (p=0.03, Supplementary Figure SIII). The apportion of MPs showed 
no observable differences depending on the type of apheresis (Supplemental data, Table SI), though 
the study was not powered on this basis. 
 
MP fatty acid concentration and profile pre- versus post-apheresis 
Little is known about the lipid concentration of MPs, thus we sought to determine the fatty acid 
concentration and profile of MPs compared with that of the corresponding plasma and to observe the 
effect of apheresis. Total plasma fatty acid concentration decreased following apheresis (8.1 ± 1.3 to 
4.6 ± 0.8 mM; p = 0.01) though this was not mirrored in the MP fraction (Figure 3A and C 
respectively). Five individual fatty acids were altered in the plasma following apheresis (p<0.05): 
C14:0 (myristic acid); C18:0 (steric acid); C18:1n7 (cis-vaccenic acid); C20:5n3 (eicosapentaenoic 
acid) and C22:3n3 (docosatrienoic acid), the former three also being altered in the MP fraction 
(p<0.05, Figure 3B and D respectively). Interestingly, comparison of the compartments; plasma and 
MPs, revealed 10 fatty acids differed in composition (p<0.05). This was true in pre- and post-
apheresis samples however the ten fatty acids were not the same. Comparing FH to healthy 
volunteers, both plasma and MP fatty acid concentration was elevated in individuals with FH (p=0.02 
and p=0.01 Supplementary Figure SIVA and C respectively). Eight fatty acids were different in both 
plasma and MPs comparing healthy volunteers and individuals with FH (p<0.05, Supplementary 
Figure SIVB and D respectively), and apheresis had a similar effect on fatty acids in either 
compartment. This was consistent with all types of apheresis received (Supplemental data, Table SI).  
 
MP thrombin generation 
Thrombin generation of MPs was analysed pre- to post-apheresis and was also correlated with total 
MP concentrations. No change was observed in MP peak thrombin generation pre- to post-apheresis 
(14.8 ± 2.9 to 16.6 ± 4.1 nM, p = 0.6). However, MP thrombin generation over time (area under the 
curve, AUC) was positively correlated with MP concentration measured by TRPS (np100) and NTA 
(r = 0.626, p = 0.001 and r = 0.424, p = 0.04 respectively). Thrombin AUC showed no correlation 
with MP concentration measured by TRPS (np200). Furthermore, when tissue factor was added to 
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MPs (to exogenously initiate maximum thrombin generation), thrombin AUC no longer correlated 
with MP concentration.  
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Discussion 
Circulating MPs are reportedly elevated in a number of diseases including in patients with severe 
hypercholesterolemia
21,29
. The present study shows novel data regarding the effects of apheresis on 
MP size, concentration, origin, fatty acid concentration and thrombin generation in patients with FH. 
Our data demonstrate that apheresis reduces circulating MP concentration, the majority of which are 
Annexin V positive MPs derived from platelets. 
Several methods exist to measure MPs, though often the technique employed is heavily dictated by 
the research question and protocol, and each exhibits unique advantages/limitations. Thus we sought 
to employ two well-established methods for MP measurement in order to capture the full spectrum of 
MP sizes. To our knowledge, TRPS and NTA have not previously been subjected to a direct 
comparison in biological samples. Our data illustrate that the range of detectability of TRPS (np100 
and np200) and NTA are similar, and although they differ vastly in reported MP concentration 
reported, taken together there is considerable agreement.  
No change was observed with TRPS or NTA in mode particle size pre- versus post-apheresis. TRPS 
using the np200 and NTA showed a fall in MP concentration pre- versus post-apheresis. MPs within 
the range of 200-250 nm were reduced the most pre- versus post-apheresis which is much greater than 
the size of LDL particles
30
, indicating the techniques are measuring a reduction MPs and not LDL. 
MP concentration did not fall when measured with TRPS using the np100. This further supports that 
the observed fall in MP concentration by the np200 and NTA was not due to either technique 
detecting LDL, as the particulate size of LDL lies within the sensitivity of the np100 pore range. MPs 
were also shown to be elevated in the exosomal range in individuals with FH compared to healthy 
volunteers. Total MP concentration also appears elevated in individuals with FH though this did not 
quite reach significance.  
Flow cytometric measurement of MPs revealed no changes in Annexin V positivity or cellular origin 
following apheresis. In keeping with previous data 
21,31,32
 platelet-MP occupied the majority of the MP 
population (88.9 ± 13%). Taken together with the fall in MP concentration this would suggest that 
apheresis non-selectively removes MPs, the majority of which are Annexin V positive and derived 
from platelets. These MPs have not only been shown to be elevated in a variety of disease states
33–38
 
but also to promote coagulation
19
, atherosclerotic plaque formation
39
 and to be associated with 
atherothrombotic events
35
. Non-selective removal of these MPs by apheresis may reduce the risk of 
thrombus formation by slowing the progression of atherosclerotic lesions thereby complementing the 
effect of LDL removal. MPs in healthy volunteers were also found to be mainly Annexin V positive 
and of platelet origin. It would appear that individuals with FH have a greater number of these 
circulating Annexin V/platelet positive MPs. Individuals with FH had a greater apportion of 
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endothelial-derived MPs, perhaps suggesting a greater level of endothelial activation compared to 
healthy volunteers, although the percentage of the total was still low (<2%). 
GC-FID was used to measure fatty acid concentration and composition in plasma and MPs. The 
relative atheroprotective mechanisms of unsaturated and polyunsaturated fatty acids are well 
documented
40
 as are the data implicating saturated fatty acids in arterial wall lipid accumulation and 
atherosclerotic plaque formation
41
. MPs have been shown to carry a specific cargo of proteins, genetic 
material and small molecules including fatty acids
42
 that can initiate a pro-inflammatory response in 
target cells
20
. Here, total fatty acid concentration of plasma was decreased following apheresis, 
however MP fatty acid levels did not change following apheresis. Thus, although the overall number 
of MPs decreases pre- versus post-apheresis, the fatty acid concentration per MP remains the same. 
Interestingly, apheresis seemed to affect individual fatty acids differently in plasma compared with 
the MP fraction; however the physiological relevance of this remains to be elucidated. Furthermore, 
when plasma was directly compared with the MP fraction, the apportion of fatty acids were found to 
be different between compartments.  This suggests that the fatty acid composition of MPs is 
independent to that of surrounding plasma, a concept we have previously found in a separate cohort of 
patients with polycystic ovary syndrome (unpublished data). Several fatty acids were different in 
individuals with FH compared to healthy volunteers in both plasma and MPs, however affected fatty 
acids and the trends (i.e. increase or decrease) were the same. Similarly to the findings in FH, in 
healthy volunteers the fatty acid composition of MPs did not reflect that of plasma. 
The potential of MPs to generate thrombin was assessed using CAT. No change was observed in MP 
peak thrombin generation pre- versus post-apheresis. However, total MP concentration measured by 
either TRPS (np100) or NTA showed a positive correlation with the total thrombin AUC whereas MP 
concentration measured by TRPS (np200) showed no correlation. Taken together, this suggests a 
reduction in MPs is associated with decreased thrombin generation capacity and that smaller MPs, 
particularly exosomes, are associated with an increased total thrombin generation over time. We 
conclude this on the basis that both TRPS (np100) and NTA have an increased sensitivity for MPs in 
the exosomal range compared to TRPS (np200) (Supplemental Figure SI). Furthermore, individuals 
with FH were shown to have an increased circulating population of smaller MPs compared with 
healthy individuals (Supplemental Figure SII). Both TRPS (np100) and NTA showed a trend towards 
reduction in exosomal populations of MPs following apheresis (Figure 1B/F respectively), though this 
did not reach significance. This could suggest that the increased circulating population of exosomes in 
individuals with FH makes their MP fraction more procoagulant. Apheresis treatment non-selectively 
removes MPs and could potentially reduce the procoagulant potential of exosomes and smaller MPs. 
Our results confirm MPs have endogenous TF activity and can stimulate thrombin generation, a 
finding in keeping with previous research
43,44
. When exogenous TF was added to MPs to stimulate 
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thrombin generation, the correlation between MP concentration and AUC was lost reflecting 
maximum thrombin generation. 
Patients in this study received apheresis based on individual clinical requirements resulting in the use 
of 3 different types of apheresis treatment. Though there was no observable difference between 
apheresis technique and MP concentration (Supplemental Table SI), the current study was not 
designed to assess this. In vitro studies have shown the surface morphology of the adsorbent polymer 
may affect MP production
45
, though this requires confirmation in vivo. FH patients were studied as 
part of their routine clinical outpatient treatment. Clearly, having now established apheresis directly 
influences MP concentration, longitudinal studies will help to establish whether the reduction in 
atherogenic MPs is maintained whilst further exploring the physiological relevance this reduction in 
MPs has in regards to CVD pathology. The thrombin generation of patient MP samples was measured 
in the presence of pooled, healthy plasma to specifically test the activity of MPs as opposed whole 
patient plasma (that would likely reflect the total influence of apheresis). Future studies should assess 
the procoagulant activity of plasma pre- to post-apheresis to confirm this reduction in atherogenic 
MPs. Finally, Annexin V binding was used to classify MP populations for identification of cellular 
origin using flow cytometry. It is acknowledged that many flow cytometers have a practical lower 
limit of around 200 nm. Therefore smaller MPs, particularly exosomes are below the detectability of 
these machines, and the fluorescence data obtained from a given sample does not completely reflect 
the full range of MP sizes observed by NTA and TRPS Despite this, flow cytometry is the most 
reliable technique to assess surface antigen expression of MPs. Importantly, NTA and TRPS confirm 
MPs within the range of 200-250 nm were reduced the most pre- versus post-apheresis and are likely 
reflected by the flow cytometric results. The use of Annexin V positivity to identify MP populations is 
used widely 
31,46,47
 but has recently been questioned
48
. As the majority (~90%) of MPs here were 
Annexin V positive, we chose to accept this as our MP population for subsequent staining. Our 
rationale was based on the fact that despite not all MPs binding Annexin V, only Annexin V positive 
MPs have been shown to possess procoagulant activity
48
. 
In summary, apheresis reduces the concentration of circulating MPs in patients with FH, the majority 
of which are Annexin V and platelet positive. Though MP concentration is reduced, apheresis has no 
effect on the total fatty acid concentration of MPs. Fatty acid composition of MPs is unique and does 
not reflect that of surrounding plasma. Each compartment is affected differently by apheresis though 
the clinical relevance of this requires further investigation. MP concentration (particularly in the 
exosomal range) was found to positively correlate with total thrombin generation, suggesting that a 
reduction in MP concentration via apheresis in FH may reduce the ability of MPs to produce 
thrombin. The removal of MPs that are predominantly Annexin V and platelet-derived is a novel 
finding, supporting the notion that apheresis may have beneficial cardiovascular effects beyond 
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lipoprotein removal. Future work should establish whether MP reduction during apheresis correlates 
with the longer-term benefits of this treatment. 
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Table 1: Biochemical and physiological measurements pre- and post-apheresis. Data are 
presented as mean ± SEM or median (range). n=12. TC: total cholesterol, hsCRP: high sensitivity C-
reactive protein, BP: blood pressure, bpm: beats per minute. * denotes statistical significance. 
Table 2: Fatty acid composition of the plasma and MP fraction. Individual fatty acid composition 
of the plasma and MPs were directly compared in pre-apheresis and post-apheresis samples. Data are 
presented as mean ± SEM (n=12). * denotes statistical significance. 
Figure 1: MP concentration and size distributions pre- and post-apheresis. MP size and 
concentration was measured in pre- and post-apheresis samples using TRPS (np100 and np200) and 
NTA. Mean concentration of MPs pre- and post-apheresis is shown for TRPS np100 (A), np200 (C) 
and NTA (E). Size/concentration distribution of MPs pre- and post-apheresis is shown for TRPS 
np100 (B), TRPS np200 (D) and NTA (F). Concentrations are given in particles/mL of plasma. Data 
are presented as mean ± SEM (n=12). 
*
p<0.05.  
Figure 2: MP origin following apheresis. MPs from pre and post-apheresis samples were analyzed 
by flow cytometry to determine cellular origin. Forward and side scatter areas (FSC-A and SSC-A 
respectively) of platelets from fresh plasma were used to determine a submicron gate where only 
Annexin V positive MPs were analyzed. A representative dot blot of FSC-A vs. SSC-A indicates the 
position of the MP gate (A, kept consistent for all samples). Samples were stained with Annexin V 
(B), CD41, CD144, CD235a and CD11b to identify the proportion derived from platelets, endothelial 
cells, erythrocytes and monocytes respectively (C).  Data are presented as mean ± SEM (n=12). 
Figure 3: GC-FID analysis of MPs following apheresis. Total fatty acid concentration of plasma 
and MPs (A and C respectively) followed by fatty acid profiling to determine compositional changes 
pre- to post-apheresis (B and D respectively). Data are presented as mean ± SEM. (n=12) 
*
p <0.05, 
**
p<0.01. 
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TABLE 1 
 Pre-Apheresis Post-Apheresis % change p value 
TC (mmol/L) 6.1 ± 0.5 2.7 ± 0.2 - 57.1 <0.0001* 
HDL (mmol/L) 1.1 (0.4-2.3) 0.9 (0.2-2.1) - 21.0 0.003* 
Triglycerides (mmol/L) 1.8 ± 0.2 0.9 ± 0.1 - 50.0 <0.0001* 
LDL (mmol/L) 4.1 ± 0.4 1.4 ± 0.2 - 66.1 <0.0001* 
TC/HDL 5.8 (3.3-10.0) 3.1 (1.9-8.2) - 41.9 0.0005* 
Glucose (mmol/L) 5.7 ± 0.3 6.1 ± 0.3 8.4 0.07 
hsCRP (mg/L) 0.8 (0.2-16.9) 0.6 (0.2-13.8) - 29.8 0.003* 
Systolic BP (mmHg) 140 ± 5 148 ± 6 6.5 0.02* 
Diastolic BP (mmHg) 81.8 ± 2.8 82.8 ± 2.7 1.4 0.45 
Heart rate (bpm) 55.8 ± 2.9 58.8 ± 3.4 5.8 0.09 
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TABLE 2 
 PRE APHERESIS POST-APHERESIS 
Fatty acid Plasma 
composition 
(%) 
MP 
composition 
(%) 
p value Plasma 
composition 
(%) 
MP 
composition 
(%) 
p value 
C14:0 0.6 ± 0.1 1.09  ± 0.1 0.04* 0.9 ± 0.1 0.6 ± 0.07 0.008* 
C14:1 0.04 ± 0.01 0.1 ± 0.02 0.006* 0.06 ± 0.1 0.1 ± 0.08 0.4 
C16:0 15.7 ± 3.2 27.3 ± 3.2 0.07 10.5 ± 3.9 25.1 ± 1.2 0.002* 
C16:1n7 2.5 ± 0.6 3.4 ± 0.4 0.4 2.0 ± 0.8 4.6 ± 0.7 0.02* 
C18:0 5.0 ± 0.8 8.2 ± 0.9 0.07 3.1 ± 1.3 10.6 ± 0.6 <0.001* 
C18:1n9 15.0 ± 4.2 6.2 ± 3.3 0.04* 10.1 ± 6.0 17.7 ± 5.4 0.4 
C18:1n7 11.3 ± 4.2 32.5 ± 3.4 0.003* 31.8 ± 7.0 17.4 ± 5.4 0.1 
C18:2n6 22.2 ± 5.8 13.3 ± 1.7 0.03* 14.0 ± 3.6 15.3 ± 1.2 0.7 
C20:1 0.4 ± 0.1 0.3 ± 0.03 0.6 0.4 ± 0.06 0.4 ± 0.07 0.3 
C20:2n6 1.7 ± 1.0 0.6 ± 0.09 0.2 1.5 ± 0.1 0.8 ± 0.09 <0.001* 
C20:5n3 0.9 ± 0.2 0.7 ± 0.15 0.03* 2.2 ± 0.4 0.9 ± 0.15 0.002* 
C22:0 0.3 ± 0.05 0.14 ± 0.06 0.02* 0.5 ± 0.07 0.14 ± 0.04 0.001* 
C22:3n3 0.1 ± 0.03 0.15 ± 0.09 0.7 0.2 ± 0.04 0.02 ± 0.01 <0.001* 
C22:3n6 0.4 ± 0.1 0.2 ± 0.1 0.09 0.9 ± 0.4 0.03 ± 0.03 0.004* 
C22:5n3 0.2 ± 0.06 0.07 ± 0.04 0.04* 0.2 ± 0.1 0.3 ± 0.3 0.8 
C22:6n3 1.2 ± 0.2 1.1 ± 0.2 0.09 2.4 ± 0.6 1.2 ± 0.2 0.09 
C24:0 0.07 ± 0.03 0.002 ± 0.002 0.009* 0.2 ± 0.05 0.02 ± 0.02 0.003* 
C24:1n9 0.9 ± 0.2 0.2 ± 0.1 0.006* 1.6 ± 0.7 0.04 ± 0.02 0.08 
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FIGURE 3 
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